Literature DB >> 29170253

Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.

Steven Coutre1, Alessandra Tedeschi2, Tadeusz Robak3, Paul M Barr4, Carolyn Owen5, Osnat Bairey6,7, Jan Burger8, Cathy Zhou9, Lori Styles9, Danelle F James9, Thomas J Kipps10.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29170253      PMCID: PMC6058772          DOI: 10.3324/haematol.2017.175380

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  2 in total

1.  Methods for adjusting for bias due to crossover in oncology trials.

Authors:  K Jack Ishak; Irina Proskorovsky; Beata Korytowsky; Rickard Sandin; Sandrine Faivre; Juan Valle
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

2.  Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

Authors:  Jan A Burger; Alessandra Tedeschi; Paul M Barr; Tadeusz Robak; Carolyn Owen; Paolo Ghia; Osnat Bairey; Peter Hillmen; Nancy L Bartlett; Jianyong Li; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Ann Janssens; Fritz Offner; Jiří Mayer; Michael O'Dwyer; Andrzej Hellmann; Anna Schuh; Tanya Siddiqi; Aaron Polliack; Constantine S Tam; Deepali Suri; Mei Cheng; Fong Clow; Lori Styles; Danelle F James; Thomas J Kipps
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

  2 in total
  3 in total

1.  Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.

Authors:  Steven E Coutre; John C Byrd; Peter Hillmen; Jacqueline C Barrientos; Paul M Barr; Stephen Devereux; Tadeusz Robak; Thomas J Kipps; Anna Schuh; Carol Moreno; Richard R Furman; Jan A Burger; Michael O'Dwyer; Paolo Ghia; Rudolph Valentino; Stephen Chang; James P Dean; Danelle F James; Susan M O'Brien
Journal:  Blood Adv       Date:  2019-06-25

2.  Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.

Authors:  Tadeusz Robak; Jan A Burger; Alessandra Tedeschi; Paul M Barr; Carolyn Owen; Osnat Bairey; Peter Hillmen; David Simpson; Sebastian Grosicki; Stephen Devereux; Helen McCarthy; Steven E Coutre; Hang Quach; Gianluca Gaidano; Zvenyslava Maslyak; Don A Stevens; Carol Moreno; Devinder S Gill; Ian W Flinn; John G Gribben; Ahmad Mokatrin; Mei Cheng; Lori Styles; Danelle F James; Thomas J Kipps; Paolo Ghia
Journal:  Am J Hematol       Date:  2018-10-09       Impact factor: 10.047

3.  Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.

Authors:  Paul M Barr; Tadeusz Robak; Carolyn Owen; Alessandra Tedeschi; Osnat Bairey; Nancy L Bartlett; Jan A Burger; Peter Hillmen; Steven Coutre; Stephen Devereux; Sebastian Grosicki; Helen McCarthy; Jianyong Li; David Simpson; Fritz Offner; Carol Moreno; Cathy Zhou; Lori Styles; Danelle James; Thomas J Kipps; Paolo Ghia
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.